News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Mohammad Jad Moussa: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation
Photo from Mohammad Jad Moussa/X
Jun 15, 2024, 05:45

Mohammad Jad Moussa: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation

Mohammad Jad Moussa, Postdoc Fellow of GU Oncology at MD Anderson Cancer Center, shared a post on X:

“NOW IN PRESS: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy

  • GU ASCO GU24: Original multi-institutional series on off-label use of lurbi in SCBC-enriched GU cohorts Omar Alhalabi, Parminder Singh, Alan Bryce.
  • ASCO24: Phase II LASER study announcement (lurbi +/- avelumab) Saad Atiq, Andrea Apolo
  • Now: Our structured report Current Oncology with a hypothesis-testing paradigm, awaiting objective response.”

Mohammad Jad Moussa: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation Mohammad Jad Moussa: Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation

Read further.
Source: Mohammad Jad Moussa/X 

Alan Bryce Andrea Apolo ASCO GU24 cancer Current Oncology durable objective response hypothesis-testing paradigm lurbi +/- avelumab Lurbinectedin MD Anderson Cancer Center Mohammad Jad Moussa molecular-directed strategy multi-institutional series objective response off-label use Omar Alhalabi OncoDaily Oncology Parminder Singh Phase II LASER study Postdoc Fellow of GU Oncology Saad Atiq SCBC-enriched GU cohorts small cell bladder cancer TP53 mutation
Special Coverage
Blog
Dec 21, 2024, 14:10
Arif Kamal: Ensuring all people have access to the cancer navigation services that will help them live more and better days
Blog
Dec 21, 2024, 14:06
The Accelerate 2025 Annual Conference Agenda Is Here!
Blog
Dec 21, 2024, 14:03
Pioneer the future of discovery and innovation with a fully funded Bicentenary PhD Studentship at The University of Manchester
Blog
Dec 21, 2024, 14:00
NCI Division of Cancer Prevention - DHT Derived Biomarkers and COAs for Remote Monitoring and Endpoint Development
Blog
Dec 21, 2024, 13:51
The ESMO President Letter emphasises the importance of collective action to shape the future of oncology
Blog
Dec 21, 2024, 13:48
Overcoming recurrence: How research is bringing new hope for breast cancer patients - The Institute of Cancer Research
Blog
Dec 21, 2024, 13:46
IARC - Cancer Incidence in Five Continents, Vol XII
Blog
Dec 21, 2024, 13:43
National University Cancer Institute, Singapore clinicians had the exciting opportunity to present their work at the ESMO Asia 2024
Blog
Dec 21, 2024, 13:40
UICC - Welcoming the newest member, The World Hepatitis Alliance
Blog
Dec 21, 2024, 13:35
Pediatric Cancer and Blood Disorders Center of Armenia - Prioritizing the continuous education and knowledge exchange of the medical staff
Blog
Dec 21, 2024, 13:33
SIOP Europe - International Childhood Cancer Day 2025
Blog
Dec 21, 2024, 13:29
Canadian Cancer Society - How 5 organizations are working to take on cancer’s biggest issues